Inflammatory Breast Cancer  >>  NOV-002  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NOV-002 / Cellectar
NCT00499122: NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

Completed
2
41
US
Cyclophosphamide, Cytoxan, Docetaxel, Doxorubicin, Adriamycin, NOV 002, Oxidized glutathione
University of Miami
Breast Cancer
04/11
04/11

Download Options